The skin cancer market is estimated to reach a market value of USD XX million by 2026 with the market growing at a CAGR of 7.21% in the forecasted period 2018-2026.
Growing technological innovations for the development of drugs and treatment, use of combination therapies for the procedure, and increasing strategic alliances between the companies, and increased focus by companies in developing low-cost drugs are also
(EMAILWIRE.COM, November 14, 2019 ) Market Overview
Skin cancer is the most common type of cancer caused due to abnormal growth of skin cells. It is estimated that 90% of the skin cancer is caused majorly due to the solar and artificial ultraviolet radiation (UV).
World Health Organization predicts that around 2-3 million non-melanoma skin cancers and 1-1.5 million melanoma skin cancers cases are reported every year with one in three cancers diagnosed is skin cancer and one in five Americans develop skin cancer in their lifetime. It also estimated that a 10% decline in ozone layer results in an additional 0.3 mn non-melanoma cases and around 4,500 melanoma cases.
Growing incidents of skin cancers rise in global warming leading to depletion of ozone layer, increasing awareness about the treatment especially in the emerging nations, favorable reimbursement policies, high investment in R & D, and promising products in the pipeline are some of the major factors driving the growth of the market.
Available of alternate treatment options, a high cost of the treatment, significant side effects affected with the treatment of the skin cancer are the key factors restraining the growth of the market.
The skin cancer market is segmented by indication type, by treatment, end user, and by geography. By Indication type, non-melanoma cancer accounts for the most significant market value due to a large number of patients. There are currently fewer drugs available for the treatment of melanoma with meager success rate.
Basal Cancer is the most common form of skin cancer with an estimated 4.3 million cases each year followed by Squamous cell carcinoma with around 1 million cases. Surgery is the most preferred treatment option for the treatment of non-melanoma cancer due to high success rate (99%).
By Geography, United States account for the most significant market value due to increasing patients for skin cancer, the rise in product availability, reduction in product prices due to Patent expiry. Asia-pacific is growing at a faster rate in the forecasted period with the patients growth rate higher in Australia and New Zealand.
Australia also has the highest incidence rate in 2018 for non-melanoma skin cancer. The annual cost of treating skin cancers in the U.S. is estimated at 8.1 billion is about USD 4.8 billion for non-melanoma skin cancers and USD 3.3 billion for melanoma
Market Segmentation
Indication Type
Basal Cell Carcinoma
Squamous Cell Carcinoma
Malignant Melanoma
Others
Treatment Type
Chemotherapy
Surgery
Non-Invasive Treatments
Others
End User
Hospital and Clinics
Cancer Research Institutes
Others
Competitive Trends
The global skin cancer market is highly consolidated with few companies accounting for the majority of the market share. Companies are highly investing in R & D and are collaborating with other companies for developing products. Solaraze, Aldara, Erivedge, Carac are some of the major drugs for the treatment of the skin cancer in the market.
Some of the major companies in the global skin cancer market include
Roche
Meda Ab
Valeant Pharmaceuticals
Research Report Scope
Skin Cancer Product Pipeline Analysis
Skin Cancer Product Sales
Skin Cancer Market Value
Skin Cancer Market Share by Geography and Product type
Skin Cancer Epidemiology
Skin Cancer Product Analysis
Enquire Before Purchase: https://www.datamintelligence.com/enquiry/skin-cancer-market
Download free sample: https://www.datamintelligence.com/download-sample/skin-cancer-market
about US
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Skin cancer is the most common type of cancer caused due to abnormal growth of skin cells. It is estimated that 90% of the skin cancer is caused majorly due to the solar and artificial ultraviolet radiation (UV).
World Health Organization predicts that around 2-3 million non-melanoma skin cancers and 1-1.5 million melanoma skin cancers cases are reported every year with one in three cancers diagnosed is skin cancer and one in five Americans develop skin cancer in their lifetime. It also estimated that a 10% decline in ozone layer results in an additional 0.3 mn non-melanoma cases and around 4,500 melanoma cases.
Growing incidents of skin cancers rise in global warming leading to depletion of ozone layer, increasing awareness about the treatment especially in the emerging nations, favorable reimbursement policies, high investment in R & D, and promising products in the pipeline are some of the major factors driving the growth of the market.
Available of alternate treatment options, a high cost of the treatment, significant side effects affected with the treatment of the skin cancer are the key factors restraining the growth of the market.
The skin cancer market is segmented by indication type, by treatment, end user, and by geography. By Indication type, non-melanoma cancer accounts for the most significant market value due to a large number of patients. There are currently fewer drugs available for the treatment of melanoma with meager success rate.
Basal Cancer is the most common form of skin cancer with an estimated 4.3 million cases each year followed by Squamous cell carcinoma with around 1 million cases. Surgery is the most preferred treatment option for the treatment of non-melanoma cancer due to high success rate (99%).
By Geography, United States account for the most significant market value due to increasing patients for skin cancer, the rise in product availability, reduction in product prices due to Patent expiry. Asia-pacific is growing at a faster rate in the forecasted period with the patients growth rate higher in Australia and New Zealand.
Australia also has the highest incidence rate in 2018 for non-melanoma skin cancer. The annual cost of treating skin cancers in the U.S. is estimated at 8.1 billion is about USD 4.8 billion for non-melanoma skin cancers and USD 3.3 billion for melanoma
Market Segmentation
Indication Type
Basal Cell Carcinoma
Squamous Cell Carcinoma
Malignant Melanoma
Others
Treatment Type
Chemotherapy
Surgery
Non-Invasive Treatments
Others
End User
Hospital and Clinics
Cancer Research Institutes
Others
Competitive Trends
The global skin cancer market is highly consolidated with few companies accounting for the majority of the market share. Companies are highly investing in R & D and are collaborating with other companies for developing products. Solaraze, Aldara, Erivedge, Carac are some of the major drugs for the treatment of the skin cancer in the market.
Some of the major companies in the global skin cancer market include
Roche
Meda Ab
Valeant Pharmaceuticals
Research Report Scope
Skin Cancer Product Pipeline Analysis
Skin Cancer Product Sales
Skin Cancer Market Value
Skin Cancer Market Share by Geography and Product type
Skin Cancer Epidemiology
Skin Cancer Product Analysis
Enquire Before Purchase: https://www.datamintelligence.com/enquiry/skin-cancer-market
Download free sample: https://www.datamintelligence.com/download-sample/skin-cancer-market
about US
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results.
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results.